Comparison of free light chain assays: Freelite and N latex in diagnosis, monitoring, and predicting survival in light chain amyloidosis

American Journal of Clinical Pathology

Volumn 146, Issue 1, 2016, Pages 78-85

  Mahmood, Shameem ^a   Wassef, Nancy L ^b   Salter, Simon J ^b   Sachchithanantham, Sajitha ^a   Lane, T ^a   Foard, D ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a   Wechalekar, Ashutosh D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Freelite; Light chain amyloidosis; Light chain assays; N Latex; Prognostic utility

Indexed keywords

AMYLOID P COMPONENT; EPITOPE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENGLAND; FEMALE; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOASSAY ANALYZER; LATEX AGGLUTINATION TEST; LATEX AGGLUTINATION TEST KIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PROCEDURES; SENSITIVITY AND SPECIFICITY;

AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84982106573     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/ajcp/aqw079     Document Type: Article

References (21)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
2. Gertz MA, Lacy MQ, Dispenzieri A, et al. Amyloidosis. Best Pract Res Clin Haematol. 2005;18:709-727.
3. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
4. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-224.
5. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light chain measurement in AL amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126-5129.
6. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol. 2005;79:319-328.
7. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia. 2012;26:2317-2325.
8. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989-995.
9. Te Velthuis H, Knop I, Stam P, et al. N Latex FLC-new monoclonal high performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49:1323-1332.
10. Dispenzieri A, Gertz M, Kyle R, et al. Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751-3757.
11. Vercammen M, Meirlaen P, Broodtaerts L, et al. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clinica Chimica Acta. 2011;412:1798-1804.
12. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
13. Briand PY, Decoux O, Caillon H, et al. Analytical performance of the serum free light chain assay. Clin Chem Lab Med. 2010;48:73-79.
14. Tate J, Bazeley S, Sykes S, et al. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev. 2009;30:131-140.
15. Kim H-S, Kim HS, Shin K-S, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. BioMed Res Int. 2014;2014:7.
16. Sharrod-Cole H, Matters D, Showell P, et al. Serum free light chain assessments: comparison of precision and linearity. Biochemica Clin. 2013;37:390a.
17. Lock R, Saleem R, Roberts E, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem. 2013;50:255-261.
18. Pretorius CJ, Klinberg S, Tate J, et al. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem. 2012;49:450-455.
19. Barnidge DR, Kohlhagen MC, Zheng S, et al. Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. J Neuroimmunol. 2015;288:123-126.
20. Mollee P, Tate JR, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med. 2013;51:2303-2310.
21. Wechalekar A, Schonland SO, Kastritis E, et al. European collaborative study of treatment outcomes in 346 patients with systemic AL amyloidosis with Mayo stage III disease. J Clin Oncol. 2013;30:989-995.